Surgical patients
Conditions
Interventions
Experimental group:Intravenous infusion of 6% HES 130/0.4
Control group:Intravenous infusion of sodium acetate Ringer injection
Sponsors
The Frist Affiliated Hospital of the air force Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Undergo elective endoscopic gastrointestinal surgery. 2. ASA I-II. 3. Aged 18 years. 4. A written informed consent has been provided. 5. Chinese population. 6. In accordance with the requirements of the approved label, receive 6% Wanheng and / or sodium acetate Ringer injection on the basis of normal clinical practice.
Exclusion criteria
Exclusion criteria: Exclusion criteria. 1. Participated in other studies in the past 3 months. 2. Pregnant and / or lactating women. 3. Body mass index ((BMI)) >= 30. 4. Intracranial or cerebral hemorrhage, renal insufficiency (male SCr > 140 umol / L, female SCr > 120 umol / L and / or oliguria / anuria) or renal replacement therapy (e.g. dialysis), severe liver function injury (ALT and / or AST exceeding 2 times the normal limit), congestive heart failure, pulmonary edema. 5. Serious disorders of internal environment, such as hypernatremia or hyperchloremia, hyperkalemia or severe alkalosis, etc. 6. Critically ill patients, including patients with sepsis. 7. Liquid overload. 8. Dehydration. 9. Bleeding and coagulation disorders or hemorrhagic diseases. 10. Organ transplant patients. 11. Burns. 12. Hypoalbuminemia (serum albumin < 35g/L). 13. Suffering from mental illness. 14. Patients who are known to be allergic to any ingredient of 6% Wanheng ?or Sodium Acetate Ringer injection and / or have any contraindications to Sodium Acetate Ringer injection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum creatinine; | — |
Countries
China
Contacts
Public ContactXiong Lize
The First Affiliated Hospital of Air Force Military Medical University
Outcome results
None listed